Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company focused on finding treatments for diseases that involve mitochondrial dysfunction. Mitochondria are crucial for normal organ function, and dysfunctional mitochondria are involved in rare genetic diseases and common age-related diseases. The company believes that their lead candidate, elamipretide, could successfully treat metabolic cardiomyopathies, mitochondrial diseases involving nuclear DNA mutations, and ophthalmic diseases related to mitochondrial dysfunction.